BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bertani L, Fornai M, Fornili M, Antonioli L, Benvenuti L, Tapete G, Baiano Svizzero G, Ceccarelli L, Mumolo MG, Baglietto L, de Bortoli N, Bellini M, Marchi S, Costa F, Blandizzi C. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther 2020;52:284-91. [PMID: 32506635 DOI: 10.1111/apt.15870] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Lamb CA, Saifuddin A, Powell N, Rieder F. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology 2022;162:1525-42. [PMID: 34995532 DOI: 10.1053/j.gastro.2021.09.077] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Cusato J, Bertani L, Antonucci M, Tomasello C, Caviglia GP, Dibitetto S, Massano A, Mangia M, Mula J, Ceccarelli L, Costa F, Zanzi F, Astegiano M, Ribaldone DG, D'Avolio A. Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. Pharmaceuticals (Basel) 2021;14:1230. [PMID: 34959633 DOI: 10.3390/ph14121230] [Reference Citation Analysis]
3 Huang F, Thokerunga E, He F, Zhu X, Wang Z, Tu J. Research progress of the application of mesenchymal stem cells in chronic inflammatory systemic diseases. Stem Cell Res Ther 2022;13:1. [PMID: 34998430 DOI: 10.1186/s13287-021-02613-1] [Reference Citation Analysis]
4 Cao Y, Dai Y, Zhang L, Wang D, Hu W, Yu Q, Wang X, Yu P, Liu W, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin. J Inflamm Res 2021;14:6409-19. [PMID: 34880643 DOI: 10.2147/JIR.S342846] [Reference Citation Analysis]
5 Atreya R, Neurath MF, Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front Med (Lausanne) 2020;7:517. [PMID: 32984386 DOI: 10.3389/fmed.2020.00517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
6 Ezirike Ladipo J, He Z, Chikwava K, Robbins K, Beri J, Molle-Rios Z. Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort. J Pediatr Gastroenterol Nutr 2021;73:352-7. [PMID: 34117193 DOI: 10.1097/MPG.0000000000003201] [Reference Citation Analysis]
7 Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, Benvenuti L, Facchin S, D'antongiovanni V, Lorenzon G, Ceccarelli L, Baglietto L, de Bortoli N, Bellini M, Costa F, Savarino EV, Fornai M. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.03.008] [Reference Citation Analysis]
8 Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021;6:589-95. [PMID: 34019798 DOI: 10.1016/S2468-1253(21)00065-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chen Y, Li H, Feng Q, Shen J. Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients. Front Pharmacol 2021;12:654985. [PMID: 33986682 DOI: 10.3389/fphar.2021.654985] [Reference Citation Analysis]
10 Giachero F, Jenke A, Zilbauer M. Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine. Expert Rev Clin Immunol 2021;17:871-81. [PMID: 34142929 DOI: 10.1080/1744666X.2021.1945442] [Reference Citation Analysis]
11 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cao Y, Dai Y, Zhang L, Wang D, Yu Q, Hu W, Wang X, Yu P, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay. Clin Biochem 2021:S0009-9120(21)00310-6. [PMID: 34843732 DOI: 10.1016/j.clinbiochem.2021.11.011] [Reference Citation Analysis]
13 Nishioka K, Ogino H, Chinen T, Ihara E, Tanaka Y, Nakamura K, Ogawa Y. Mucosal IL23A expression predicts the response to Ustekinumab in inflammatory bowel disease. J Gastroenterol 2021;56:976-87. [PMID: 34448069 DOI: 10.1007/s00535-021-01819-7] [Reference Citation Analysis]
14 Mezghiche I, Yahia-Cherbal H, Rogge L, Bianchi E. Novel approaches to develop biomarkers predicting treatment responses to TNF-blockers. Expert Rev Clin Immunol 2021;17:331-54. [PMID: 33622154 DOI: 10.1080/1744666X.2021.1894926] [Reference Citation Analysis]
15 Yu B, Yin YX, Tang YP, Wei KL, Pan ZG, Li KZ, Guo XW, Hu BL. Diagnostic and Predictive Value of Immune-Related Genes in Crohn's Disease. Front Immunol 2021;12:643036. [PMID: 33936061 DOI: 10.3389/fimmu.2021.643036] [Reference Citation Analysis]
16 Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, Ferrante M, Cleynen I, De Hertogh G, Vermeire S. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab032. [PMID: 33624092 DOI: 10.1093/ibd/izab032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]